Special Issue "BARD1 in Cancer"
Deadline for manuscript submissions: 15 August 2020.
2. BARD1 Life Sciences Limited, 431 Roberts Road, Subiaco WA 6008, Australia
Interests: BARD1, BRCA1, BARD1 splicing, BARD1 isoforms, breast cancer, ovarian cancer, lung cancer, biomarkers, treatment targets
2. Department of Biology and Medical Genetics, Medical University of Gdansk, Debinki 1 St., 80-210 Gdansk, Poland
Interests: genetic testing; epigenetic; hereditary cancer; breast and ovarian cancer
BARD1 is the main binding partner of BRCA1, and it is required for its stability and tumor-suppressor functions. While upregulation of alternatively spliced BARD1 isoforms is a common finding in many epithelial cancers, germline mutations are a relatively rare finding, with conflicting reports on their role in the predisposition to cancer. Thus, understanding the cellular functions of BARD1 and its role as both a potential prognostic marker and a possible risk factor in cancer predisposition is of the highest importance.
In this Special Issue, we welcome reviews, short reports, and original articles covering many aspects of BARD1 biology. These include but are not limited to mutation testing, alternative splicing findings, and the functional relationship between networks representing co-expression of well-known BARD1 isoforms and their association with a disease.
We look forward to your contributions.
Dr. Irmgard Irminger-Finger
Dr. Magda Ratajska
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- BARD1 mutations
- BARD1 splicing
- BARD1 DNA repair functions